Quick Answer
Head-to-head trials show tirzepatide (Mounjaro) produces 20% weight loss vs 14% for semaglutide (Ozempic). But cost matters: generic semaglutide is available in India from Rs 1,290/month while Mounjaro costs more. A GLP-1 specialist can help you choose.
Free Consultation
Have questions about GLP-1 Therapy?
Enter your phone number — a specialist calls you back in 30 minutes. Free, no commitment.
🔒 Confidential · No spam · 10,000+ patients helped
If you have been researching GLP-1 medications in India, you have almost certainly faced the same question: should I take Ozempic or Mounjaro? Both are weekly injections. Both cause significant weight loss. Both improve blood sugar in people with type 2 diabetes. So which one actually works better — and does the difference justify the extra cost? New clinical trial data published in the New England Journal of Medicine and confirmed by a 2026 real-world study now give us the clearest answer yet. Here is what Indian patients need to know before making this decision.
The SURMOUNT-5 Trial: The First Head-to-Head Test
For years, doctors and patients compared Ozempic and Mounjaro using results from separate clinical trials conducted in different populations at different times — a method that is inherently imprecise. The SURMOUNT-5 trial changed that by placing tirzepatide (Mounjaro) and semaglutide (Wegovy) directly against each other in the same randomised controlled trial for the first time. The results were published in the New England Journal of Medicine, the most prestigious medical journal in the world.
The trial enrolled adults with obesity or overweight who did not have type 2 diabetes and followed them over 72 weeks. Participants in the tirzepatide group lost an average of 20.2% of their body weight. Those in the semaglutide group lost an average of 13.7%. Put simply, tirzepatide produced nearly 47% more weight loss than semaglutide over the same period. Tirzepatide users were also significantly more likely to achieve clinically meaningful weight loss targets — more than twice as many tirzepatide users lost at least 25% of their body weight compared to semaglutide users.
Both drugs were well tolerated, with similar side effect profiles: nausea, vomiting, and gastrointestinal symptoms were the most common complaints in both groups, and both were generally mild to moderate in severity. Importantly, the dropout rate due to side effects was not significantly higher in the tirzepatide group, suggesting that tirzepatide is not harder to tolerate despite its greater efficacy.
Why Does Tirzepatide Work Better?
Free Consultation
Have questions about GLP-1 Therapy?
Enter your phone number — a specialist calls you back in 30 minutes. Free, no commitment.
🔒 Confidential · No spam · 10,000+ patients helped
The reason for the difference comes down to how the two drugs work at the molecular level. Semaglutide acts on one receptor — the GLP-1 receptor — in the brain and gut to reduce appetite, slow stomach emptying, and improve insulin secretion. Tirzepatide is what scientists call a dual agonist: it activates both the GLP-1 receptor and a second receptor called the GIP (glucose-dependent insulinotropic polypeptide) receptor. GIP receptors are found in fat tissue and the brain, and activating them appears to amplify the appetite-suppressing and fat-burning effects of GLP-1 stimulation. This dual mechanism is why Mounjaro consistently outperforms Ozempic and Wegovy in weight loss outcomes.
Real-World Data Confirms the Clinical Trial Results
Some patients and doctors are cautious about clinical trial results because trials are conducted under carefully controlled conditions that may not reflect everyday clinical practice. A 2026 retrospective cohort study published in NCBI sought to answer exactly this question — do tirzepatide patients lose more weight than semaglutide patients in the real world?
The study analyzed six months of real-world clinical data from patients with obesity in the United States. The findings confirmed the trial results. In actual clinical practice, tirzepatide was associated with significantly greater weight loss than semaglutide, with tirzepatide users more frequently achieving the weight-reduction targets that are associated with meaningful improvements in cardiovascular and metabolic health. Tirzepatide also produced greater improvements in blood pressure, HbA1c, and cholesterol levels than semaglutide in the real-world setting.
A separate 2026 analysis published in Frontiers in Medicine reviewed all available clinical trial and real-world data and concluded that tirzepatide consistently demonstrates superior weight loss and glycaemic control across both controlled and uncontrolled settings.
What This Means for Indian Patients Specifically
Free Consultation
Have questions about GLP-1 Therapy?
Enter your phone number — a specialist calls you back in 30 minutes. Free, no commitment.
🔒 Confidential · No spam · 10,000+ patients helped
The head-to-head evidence is clear: tirzepatide (Mounjaro) is the more effective weight loss drug. But for Indian patients in 2026, the decision between Mounjaro and generic semaglutide is not purely about efficacy — cost is a significant factor. Since the Indian patent expiry of semaglutide in March 2026, generic versions have entered the market from manufacturers including Natco Pharma, Sun Pharma, and Cipla. Prices start at approximately Rs 1,290 per month, making semaglutide far more affordable than Mounjaro, which remains a branded product from Eli Lilly priced substantially higher.
The right choice depends on your clinical situation. If you have type 2 diabetes, both drugs are approved in India and your doctor can prescribe either. If you have a very high starting body weight and need maximum weight loss, the additional efficacy of tirzepatide may justify its higher cost. If cost is your primary constraint, generic semaglutide at Rs 1,290 per month still delivers clinically meaningful weight loss — the SURMOUNT-5 trial showed semaglutide users lost 13.7% of their body weight over 72 weeks, which for many Indian patients represents a transformative health improvement.
It is also worth noting that both drugs are most effective when combined with dietary changes, moderate exercise, and regular medical monitoring. A GLP-1 specialist can help you decide which drug is right for your BMI, health conditions, budget, and long-term goals — and set up the monitoring plan that will maximise your results.
Call MySurgery at 8588967050 or WhatsApp us to speak with a GLP-1 specialist. Free consultation, callback in 30 minutes.
Disclaimer: This article is based on information published on the referenced websites below and is intended for general awareness only. It is not a substitute for professional medical advice.
References: 1. New England Journal of Medicine (SURMOUNT-5 trial) — https://www.nejm.org/doi/full/10.1056/NEJMoa2416394 2. NCBI — Real-world comparative effectiveness of tirzepatide and semaglutide — https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12924827/ 3. Frontiers in Medicine — Tirzepatide vs. semaglutide narrative review — https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2026.1764664/full
MySurgery GLP-1 Team
GLP-1 Research & Patient Education
Have questions about GLP-1 Therapy?
Free consultation. Expert doctors. Callback in 30 minutes.